RxDoctor Payments DataLook up a doctor →

Alaa Abousaif, MD

Gastroenterology · Orange, CANPI 1235124108

Payments from drug & device makers

$1,786,883in general payments, 2019–2025

Across 1,514 payments — averaging $1180.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$745K
  • Capsovision, Inc.$480K
  • Madrigal Pharmaceuticals$286K
  • Bausch Health US, LLC$159K
  • Regeneron$22K
  • Boehringer Ingelheim International GmbH$22K
  • plus $74K from 44 others
$934in research payments, 2019–2025

Across 1 payment — averaging $934.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$934

What the payments were for

  • Consulting fees$5,6408%
  • Speaking & faculty fees$28,22038%
  • Travel & lodging$16,54322%
  • Food & beverage$24,14732%
  • Education$1790%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,786,883 in reported general payments places this provider in the 95th percentile of 1,885 gastroenterology providers in California.

See all gastroenterology providers in California

Medicare billing

Part B allowed, 2024
$215,899
Medicare patients
517
Services billed
2,124

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase25$61,096
LinzessLinaclotide73$50,788
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates219$12,788
Mesalamine27$12,721
Dexlansoprazole DrDexlansoprazole25$12,028
DexilantDexlansoprazole11$4,917
Lansoprazole210$4,766
Pantoprazole Sodium408$3,636
Budesonide EcBudesonide26$3,358
Omeprazole252$2,792
Famotidine206$2,760
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg107$2,179
Colesevelam Hcl12$1,101
Ondansetron OdtOndansetron26$1,087
Cholestyramine LightCholestyramine13$883

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$5,577$111,88498 claims
Takeda Pharmaceuticals U.S.A., Inc.Dexilant$5,639$4,91711 claims
SandozLansoprazole$51$4,766210 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,885 gastroenterology providers in California.

Other gastroenterology in Orange

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →